Plasma p-tau181 reduces tau-PET screening failures by ~50% (Moscoso et al., 2022), while plasma glial fibrillary acidic protein (GFAP) mediates Aβ-PET effects on tau-PET burden and cognitive decline (Pereira et al., 2021). This evidence concerns the gene MAPT and Mental deterioration.